CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors
CAMP4 Therapeutics has appointed John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors. Both bring extensive experience in RNA-based medicines to the company.
Dr. Maraganore, former CEO of Alnylam, led the development and commercialization of the first four RNAi therapeutics. He also has a background in oncology, cardiovascular, inflammatory, and metabolic diseases from his time at Millennium Pharmaceuticals.
Dr. Meyers, with over two decades in life sciences, was Senior VP of Research at Alnylam and is currently on several scientific advisory boards. She has significant expertise in developing RNA-based therapies and has held leadership roles in various biotech firms.
CEO Josh Mandel-Brehm expressed excitement about leveraging their expertise to advance CAMP4's RNA Actuating platform, aiming to upregulate gene expression to treat genetic diseases. Both advisors see potential for CAMP4 to impact a broad range of diseases through innovative RNA medicines.
CAMP4 Therapeutics ha nominato John Maraganore, Ph.D. e Rachel Meyers, Ph.D. come consulenti strategici. Entrambi portano una vasta esperienza in medicinali basati su RNA all'interno dell'azienda.
Il Dr. Maraganore, ex CEO di Alnylam, ha guidato lo sviluppo e la commercializzazione dei primi quattro terapeutici RNAi. Ha anche una formazione in oncologia, cardiovascolare, infiammatoria e malattie metaboliche grazie alla sua esperienza presso Millennium Pharmaceuticals.
La Dr.ssa Meyers, con oltre due decenni nel settore delle scienze della vita, è stata Senior VP della Ricerca presso Alnylam ed è attualmente membro di diversi comitati consultivi scientifici. Possiede una significativa esperienza nello sviluppo di terapie basate su RNA e ha ricoperto ruoli di leadership in diverse aziende biotecnologiche.
Il CEO Josh Mandel-Brehm ha espresso entusiasmo per sfruttare la loro esperienza per avanzare nella piattaforma RNA Actuating di CAMP4, che mira a regolare positivamente l'espressione genica per trattare le malattie genetiche. Entrambi i consulenti vedono un potenziale per CAMP4 di influenzare un ampio ventaglio di malattie attraverso medicinali RNA innovativi.
CAMP4 Therapeutics ha nombrado a John Maraganore, Ph.D. y Rachel Meyers, Ph.D. como asesores estratégicos. Ambos aportan una amplia experiencia en medicamentos basados en RNA a la empresa.
El Dr. Maraganore, ex CEO de Alnylam, lideró el desarrollo y la comercialización de los primeros cuatro terapéuticos de RNAi. También tiene un fondo en oncología, enfermedades cardiovasculares, inflamatorias y metabólicas de su tiempo en Millennium Pharmaceuticals.
La Dra. Meyers, con más de dos décadas en ciencias de la vida, fue Vicepresidenta Senior de Investigación en Alnylam y actualmente forma parte de varios comités asesores científicos. Tiene una significativa experiencia en el desarrollo de terapias basadas en RNA y ha ocupado roles de liderazgo en varias empresas biotecnológicas.
El CEO Josh Mandel-Brehm expresó su entusiasmo por aprovechar su experiencia para avanzar en la plataforma RNA Actuating de CAMP4, con el objetivo de aumentar la expresión génica para tratar enfermedades genéticas. Ambos asesores ven un potencial para que CAMP4 impacte en un amplio rango de enfermedades a través de medicamentos innovadores basados en RNA.
CAMP4 Therapeutics는 John Maraganore, Ph.D.와 Rachel Meyers, Ph.D.를 전략 고문으로 임명했습니다. 두 사람 모두 RNA 기반 의약품에 대한 폭넓은 경험을 회사에 제공합니다.
마라가노르 박사는 Alnylam의 전 CEO로, 첫 번째 RNAi 치료제 네 가지의 개발과 상용화를 이끌었습니다. 그는 또한 Millennium Pharmaceuticals에서의 경력으로 종양학, 심혈관, 염증 및 대사 질환에 대한 배경을 가지고 있습니다.
메이어스 박사는 생명과학 분야에서 20년 이상의 경력을 가지고 있으며, Alnylam에서 연구 부서의 수석 부사장이었으며 현재 여러 과학 자문 위원회에 참여하고 있습니다. 그녀는 RNA 기반 치료제 개발에 중대한 전문성을 보유하고 있으며 여러 생명공학 회사에서 리더십 역할을 수행한 경험이 있습니다.
CEO Josh Mandel-Brehm은 CAMP4의 RNA Actuating 플랫폼을 발전시키기 위해 그들의 전문성을 활용하게 되어 기쁘다고 표명했으며, 유전 질환 치료를 위해 유전자 발현을 증가시키는 것을 목표로 하고 있습니다. 두 고문 모두 CAMP4가 혁신적인 RNA 의약품을 통해 다양한 질환에 영향을 미칠 수 있는 잠재력을 보고 있습니다.
CAMP4 Therapeutics a nommé John Maraganore, Ph.D. et Rachel Meyers, Ph.D. en tant que conseillers stratégiques. Tous deux apportent une vaste expérience en médecines basées sur l'ARN à l'entreprise.
Le Dr Maraganore, ancien PDG d'Alnylam, a dirigé le développement et la commercialisation des quatre premiers thérapeutiques RNAi. Il a également des antécédents en oncologie, maladies cardiovasculaires, inflammatoires et métaboliques grâce à son expérience chez Millennium Pharmaceuticals.
La Dr Meyers, avec plus de deux décennies d'expérience dans les sciences de la vie, était VP Senior de la recherche chez Alnylam et fait actuellement partie de plusieurs conseils consultatifs scientifiques. Elle possède une expertise significative dans le développement de thérapies basées sur l'ARN et a occupé des rôles de leadership dans plusieurs entreprises biotechnologiques.
Le PDG Josh Mandel-Brehm a exprimé son enthousiasme à l'idée de tirer parti de leur expertise pour faire progresser la plateforme RNA Actuating de CAMP4, visant à réguler l'expression génique pour traiter les maladies génétiques. Les deux conseillers voient un potentiel pour CAMP4 d'influencer une large gamme de maladies grâce à des médicaments innovants basés sur l'ARN.
CAMP4 Therapeutics hat John Maraganore, Ph.D. und Rachel Meyers, Ph.D. als strategische Berater ernannt. Beide bringen umfangreiche Erfahrungen in RNA-basierten Medikamenten in das Unternehmen ein.
Dr. Maraganore, ehemaliger CEO von Alnylam, leitete die Entwicklung und Vermarktung der ersten vier RNAi-Therapeutika. Er hat auch einen Hintergrund in Onkologie, Herz-Kreislauf-, Entzündungs- und Stoffwechselerkrankungen aus seiner Zeit bei Millennium Pharmaceuticals.
Dr. Meyers, die über zwei Jahrzehnte Erfahrung in den Lebenswissenschaften verfügt, war Senior VP für Forschung bei Alnylam und ist derzeit in mehreren wissenschaftlichen Beratungsgremien tätig. Sie besitzt umfassende Expertise in der Entwicklung von RNA-basierten Therapien und hat Führungsrollen in verschiedenen Biotech-Unternehmen übernommen.
CEO Josh Mandel-Brehm äußerte seine Begeisterung, ihr Fachwissen zu nutzen, um die RNA Actuating-Plattform von CAMP4 voranzubringen, mit dem Ziel, die Genexpression zur Behandlung genetischer Erkrankungen zu regulieren. Beide Berater sehen Potenzial für CAMP4, eine breite Palette von Krankheiten durch innovative RNA-Medikamente zu beeinflussen.
- Appointment of industry veterans John Maraganore and Rachel Meyers as strategic advisors.
- Potential to leverage their extensive experience in RNA-based medicines for CAMP4's development.
- Positive outlook on CAMP4's RNA Actuating platform to address genetic diseases.
- No immediate financial impact or revenue figures associated with the appointments.
Industry veterans John Maraganore, Ph.D., and Rachel Meyers, Ph.D., to provide strategic guidance on the company’s RNA Actuating platform to develop a new class of RNA medicines that upregulate protein coding genes
CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company.
For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company’s programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi therapeutics, ONPATTRO®, GIVLAARI®, OXLUMO®, and LEQVIO®. Additionally, Dr. Meyers brings more than two decades of life sciences leadership, research, and development experience in RNA-based medicines, having spent nearly 14 years at Alnylam where she most recently served as Senior Vice President of Research and RNAi Lead Development. She currently sits on the company’s Scientific Advisory Board.
“We feel privileged and are delighted to welcome Drs. Maraganore and Meyers to our CAMP4 team as strategic advisors,” said Josh Mandel-Brehm, Chief Executive Officer of CAMP4. “We view their joining the team as a testament to the promise and potential of our approach for upregulating gene expression to potentially address a broad range of diseases. As we prepare for 2025, we look forward to benefiting from their insights and expertise as we advance our efforts in bringing potentially transformative RNA medicines to patients in need of disease-modifying solutions.”
Dr. Maraganore added, “The targeted upregulation of gene expression has been a long-standing challenge for the field, and by applying established and clinically validated antisense oligonucleotide technology to groundbreaking science, CAMP4 could potentially make a meaningful impact on patients across a broad range of diseases. I look forward to working with them as they pioneer the field of upregulation.”
Prior to his role at Alnylam, Dr. Maraganore led the product franchises in oncology, cardiovascular, inflammatory, and metabolic diseases for Millennium Pharmaceuticals, in addition to leadership of M&A, strategy, and biotherapeutics. Earlier in his career, Dr. Maraganore invented and spearheaded the development of ANGIOMAX® (bivalirudin) for injection while at Biogen and was also a scientist at ZymoGenetics, Inc., and the Upjohn Company. He currently serves as a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Ventures, an Executive Partner at RTW Investments, a Senior Advisor for Blackstone Life Sciences, and a Senior Advisor for Jeffries Financial Group. Beyond his leadership roles in the investment community, Dr. Maraganore also sits on the Board of Directors for multiple publicly traded companies, including Beam Therapeutics, Kymera Therapeutics, Rapport Therapeutics, and Takeda Pharmaceuticals. He received his B.A., M.S., and Ph.D. in biochemistry and molecular biology at the University of Chicago.
Dr. Meyers currently serves as a member of the Board of Directors of Korro Bio (Nasdaq: KRRO), a biopharmaceutical company focused on discovering, developing, and commercializing a new class of genetic medicines based on editing RNA, and also holds a variety of advisory roles within the biotech community. Most recently, she served as Founder and Chief Scientific Officer at Faze Medicines, a Third Rock Ventures-spawned biotech company focused on treating diseases of high unmet need through the perturbation of biomolecular condensates. Earlier in her career, Dr. Meyers was a senior scientist at Millennium Pharmaceuticals and today serves on multiple scientific advisory boards, including the National Advisory Board on Innovation and Entrepreneurship through the Department of Commerce. Furthermore, she is listed as an inventor on numerous patents and patent applications and has authored many peer-reviewed publications.
Dr. Meyers received her postdoctoral training with Lew Cantley at Harvard Medical School in signal transduction and earned her Ph.D. in biology from Nobel laureate Phil Sharp at the Massachusetts Institute of Technology in in vitro transcription. She earned her BA in Biochemistry from Brandeis University.
“I’ve had the unique opportunity to work alongside tremendously talented professionals who have led the shaping of the RNA medicines space,” said Dr. Meyers. “Having been at the forefront of these scientific breakthroughs, I believe now more than ever RNA-based therapies are poised to continue transforming how we treat patients with complex diseases. Having the opportunity to advise CAMP4 as they continue advancing the field is an extension of the work to which I’ve committed my career.”
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regRNAs, which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform™ enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. Learn more about us at www.CAMP4tx.com and follow us on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning CAMP4’s plans, objectives, expectations and intentions; the timing and results of ongoing and future clinical trials, including expectations on the timing of reporting SAD and MAD data from and seeking regulatory approval for the CMP-CPS-001 trial; its growth strategy; and cash balance guidance. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company’s current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company’s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company’s ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company’s dependence on the services of the Company’s senior management and other clinical and scientific personnel, and the Company’s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company’s ability to grow the Company’s organization, and manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of the Company’s product candidates, which is complex, and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates or any future product candidates the Company may develop; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company’s product candidates; risks related to the operations of the Company’s suppliers; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as well as other information we file with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contacts
Investor Relations:
Sandya von der Weid
LifeSci Advisors
svonderweid@lifesciadvisors.com
Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com
FAQ
Who are the new strategic advisors appointed by CAMP4?
What experience does John Maraganore bring to CAMP4?
What is Rachel Meyers' background in the biotech industry?
What is the significance of the new appointments for CAMP4?
How might the new advisors impact CAMP4's development?
